Ferozsons Laboratories Ltd 2023 AR2
The report highlights Ferozsons Laboratories Limited's financial and operational performance for the fiscal year ended June 30, 2023. The company achieved a consolidated net revenue of Rs. 11.5 billion, representing a 23% growth despite severe macroeconomic challenges, including a 40% devaluation of the Pakistani Rupee. Ferozsons expanded its product portfolio in cardiology, gastroenterology, and diabetes, and advanced its sustainability initiatives by installing a 1 MW solar power project at its Lahore headquarters. Additionally, the company actively supported various UN Sustainable Development Goals through community care programs, including hunger eradication partnerships and prison healthcare campaigns.
Company: Ferozsons Laboratories Ltd
Sector: Health Care
Country: Pakistan
Year: 2023
Type: AR2
Pages: 202
Ferozsons Laboratories Ltd
Annual Report
The report highlights Ferozsons Laboratories Limited's financial and operational performance for the fiscal year ended June 30, 2023. The company achieved a consolidated net revenue of Rs. 11.5 billion, representing a 23% growth despite severe macroeconomic challenges, including a 40% devaluation of the Pakistani Rupee. Ferozsons expanded its product portfolio in cardiology, gastroenterology, and diabetes, and advanced its sustainability initiatives by installing a 1 MW solar power project at its Lahore headquarters. Additionally, the company actively supported various UN Sustainable Development Goals through community care programs, including hunger eradication partnerships and prison healthcare campaigns.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jul 1, 2022 - Jun 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees